Treatment of the CLL with the inhibitory anti-ROR1 mAb zilovertamab, on the other hand, inhibited Wnt5a-induced increases in BCL-XL and resistance to venetoclax, indicating that this effect of Wnt5a is mediated via ROR1. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.